YAQRIT

Developing life-saving treatments for advanced liver disease

Four clinical-stage assets, one critical path

Three clinical readouts in the next fifteen months

Yaqrit is a clinical-stage biotech advancing four phase 2/3 therapeutics for advanced liver disease, an area that has seen no new approved drugs in 15 years. Built on pioneering research from UCL Liver Failure Group targeting underlying mechanisms driving disease progression, Yaqrit has 3 expected clinical readouts over the next 15 months, providing near-term valuation inflection points in a market with significant unmet need. Estimated combined commercial opportunity is over $9B. $26M equity raised to date and $24M highly competitive non-dilutive grants

ONE CRITICAL PATH: INFLAMMATION

YAQ001 Enterosorb
In the gut
Adsorbs endotoxins and resets the microbiome

YAQ002 Cytox
In the blood
Removes endotoxins, replaces dysfunctional albumin

YAQ005 Hepyx
At the receptor
Blocks TLR4, the immune sensor that triggers inflammation

YAQ006/7 Amalive
At the toxin
Scavenges ammonia, the driver of hepatic encephalopathy (HE)

THE PIPELINE AND ITS UNMET NEED



Hepatic Encephalopathy

~30-40% of cirrhosis patients

>50% mortality within 12 months

Acute-on-chronic liver failure

26% of US decompensated-cirrhosis admissions

>50% dead within 90 days

MULTIPLE NEAR-TERM MILESTONES

H2 2026
YAQ001
Phase 2a readout in PSC (primary sclerosing cholangitis)

H2 2026
YAQ006
Pivotal phase 3 initiation

H2 2027
YAQ002 *
Registrational readout (2nd generation)

H2 2027
YAQ005
Phase 2 data readout

WHY NOW · IMPROVING COMEPETITIVE DYNAMICS IN LEAD INDICATION, HE

Nov 2024
ANTIMICROBIAL RESISTANCE
Nature paper highlighted treatment for HE recurrence, rifaximin, causes resistance to last resort antibiotic

Jan 2026
PRIMARY PREVENTION FAILURE
Bausch's two phase 3s for rifaximin in HE prevention failed to meet primary endpoint. No approved treatment today

Mar 2026
AMMONIA ROLE RECOGNIZED
International Delphi consensus recognized ammonia's clinical significance in HE. Yet no ammonia scavengers are approved in HE

INVESTMENT OPPORTUNITY · SERIES A UP TO $70M

Up to $70M at the corporate level or in individual assets via wholly-owned subsidiaries, Amalive, Hepyx and Enterosorb. Milestones fall 12-36 months after each investment. Yaqrit will actively explore partnerships, out-licensing or public listing to crystallize value. Comparable liver asset transactions have each raised $40-60M upfront, with milestones ranging up to $350M (Bausch Health/DURECT; GENFIT/Versantis; Mallinckrodt/Ocera)

Contact: Troels Jordansen, CEO · Troels@Yaqrit.com · +31 6 1834 5326

LEAD FRANCHISE · AMMONIA · AMALIVE

L-ornithine phenylacetate (OPA): First-in-class ammonia scavenger reduces ammonia, a key underlying driver of hepatic encephalopathy (HE). Patent protection to 2044. Invented in UCL Liver Failure Group, acquired by Mallinckrodt for $42M + $75M contingent milestones in 2017, acquired by Yaqrit in Mallinckrodt bankruptcy

YAQ006 — OPA intravenous

Treatment of overt HE in hospital

Status Phase 3-ready, protocol FDA-aligned. US orphan drug designation and fast track

Ask $45M to fund the pivotal phase 3

Basis New phase 3 design has >85% modelled probability of success, addressing critical issues identified in phase 2b clinical design. Phase 2b showed significant dose-dependent ammonia reduction and trend to clinical improvement

YAQ007 — OPA oral

Prevention of first and recurrent overt HE

Status Adaptive phase 2b/3 in design

Ask $15M to fund phase 2b/3

Basis Phase 2a (Hepatology 2026) showed dose dependent ammonia reduction in HE patients. Ammonia scavenger class validated by prior phase 2 study with glycerol phenylbutyrate which cut HE events from 32% to 10%. No treatment approved today for primary prevention

THE REST OF THE PIPELINE

YAQ005
Hepyx

IP to 2039

TLR4 antagonist for acute-on-chronic liver failure (grade 1 and 2)

Status Phase 2a A-TANGO trial ongoing, largely funded by EU Horizon 2020; 1st data H2-27

Ask $3M to complete the trial to phase 2b readiness and FDA alignment

Basis Reduces organ and systemic inflammation. Full safety package acquired from big pharma after phase 3 failure in sepsis. Mechanism in ACLF established in Yaqrit/UCL work (J.Hepatol. 2020; Sci Adv. 2024)

YAQ001
Enterosorb

IP to 2046

Gut-restricted carbon adsorbent *(FDA regulates as drug; EU as medical device)*

Status PSC (rare disease) UK study ongoing with readout H2 2026

Ask $7M for CE mark in Europe; US FDA alignment; completion of 3 targeted trials to provide data for it to be considered a microbiome therapeutic platform

Basis Adsorbs endotoxins and resets microbiome. Safety and tolerability established in cirrhosis (Gut 2024) with supporting microbiome and inflammation data

YAQ002
Cytox Life Sciences

IP to 2044

DIALIVE liver support device

Status 1st gen CE mark; 2nd gen in randomized registrational trial ALIVER readout H2-27

Ask $2.5M to complete EU registration study together with grant award

Basis Removes endotoxins and replaces dysfunctional albumin. Trial with 1st gen device (J.Hepatol 2023) met its safety primary and significantly shortened time to ACLF resolution and improvement in CLIF-C organ failure

Clinical program funded to date by EU Horizon 2020: 733057 (ALIVER) and 945096 (A-TANGO) and NIHR Invention for Innovation award NIHR206537

LEADERSHIP

Professor Rajiv Jalan, MD, Ph.D.
Chair, Founder, CMO/CSO

Professor of Hepatology at UCL & Consultant Hepatologist at the Royal Free London. First to identify ACLF as a distinct entity; inventor of OPA and YAQ001. ~590 peer-reviewed papers (H-index: 124). Former Scientific Director, EF CLIF; former Editor-in-Chief, J. Hepatol.

Troels Jordansen
Chief Executive Officer, Board Member

35+ years in commercial & senior leadership in life sciences, including IsoTis, Genzyme and J&J Orthopaedics. Founding Partner, Altius Bioventures. Ex-CEO Glycostem Therapeutics and Check4Cancer. Two IPOs, multiple licensing deals, and public listed board work

Board Rajiv Jalan (Chair) · Troels Jordansen · Tauhid Ali, Ph.D. · Ronen Israel

Management Julie Bailey, CFO · Timothy Jenkins, Ph.D., CDO · Amrik Shah, ScD, Chief Biometrics Officer · Karen Church, Ph.D., Head of Regulatory Affairs (FDA), QA & Clinical Ops · Carrie Morgan, SVP Clinical Ops · Jan Bart, Ph.D., Clinical, Regulatory (European) & Quality Management · Michal Kowalski, SVP Operations · Darren Rubin, VP Innovation Strategy · Mary-Ann Chang, CFA, SVP Comms & Strategy